Clik here to view.
Covance Recognized with Frost & Sullivan Asia Pacific CRO Customer Value...
BURLINGTON, N.C. LabCorp (NYSE: LH), a leading global life sciences company, announced today that its Covance Drug Development business (Covance) has been awarded the 2017 Frost & Sullivan Asia...
View ArticleClik here to view.
Anika Announces Regulatory Approval for MONOVISC® in Australia for the...
BEDFORD, Mass. Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology,...
View ArticleClik here to view.
Acerus Announces Licensing of NATESTO® in South East Asian Countries
TORONTO Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting Eu Hwa Pte LTD. (“EU”) the exclusive right to market NATESTO® in Thailand, Malaysia/Brunei,...
View ArticleClik here to view.
Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery...
OSAKA, Japan & CHARLOTTESVILLE, Va. Takeda Pharmaceutical Company Limited (TSE: 4502) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to...
View ArticleClik here to view.
GenePeeks Expands Distribution to India with Exclusive Agreement with CORE...
CAMBRIDGE, Mass. GenePeeks, Inc., a computational genomics company focused on transforming disease risk analysis, today announced an exclusive distribution agreement with CORE Diagnostics, a...
View ArticleClik here to view.
武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，枢纽性2期ALTA (ALK in Lung Cancer Trial of AP26113)临床试验数据将于日本标准时间10月16日星期一下午4:30 – 4:40在国际肺癌研究学会(IASLC)第18届世界肺癌大会(WCLC)上进行口述呈报，该试验评估ALUNBRIGTM...
View ArticleClik here to view.
Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung...
HENDERSON, Nev. Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and...
View ArticleClik here to view.
Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class...
SAN DIEGO Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced updated results from its clinical trials, including the STARTRK-2 trial, of...
View ArticleClik here to view.
武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM（ブリガチニブ）のピボタル第2相ALTA試験の最新データを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502）は本日、クリゾチニブ投与中に進行した局所進行性／転移性未分化リンパ腫キナーゼ（ALK）陽性非小細胞肺がん（NSCLC）患者でALUNBRIGTM（ブリガチニブ）を評価するピボタル第2相ALTA（ALK in Lung Cancer Trial of...
View ArticleClik here to view.
Median Technologies Appoints Vivian Wang as General Manager, China and...
SOPHIA ANTIPOLIS, France Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® today announces the appointment of Vivian Wang as General Manager, China and the...
View ArticleClik here to view.
Konica Minolta and Innovation Network Corporation of Japan Close Acquisition...
TOKYO Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN: JP3300600008) and Innovation Network Corporation of Japan (“INCJ”) today announced the close of their joint acquisition of Ambry...
View ArticleClik here to view.
Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines
BURTON-ON-TRENT, England Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has today acquired International Medical Management Corporation...
View ArticleClik here to view.
MJC——古老智慧与现代渠道的结合
香港 古代风水活动可能是3,000多年前在中国发展起来的，不过它今天仍能为我们忙碌的生活带来好运、平衡与和谐。然而，像许多宝贵的历史传统一样，重要的是找到将这些活动融入现代生活的新办法。这正是mjc-fs.com的上线可以发挥影响力的地方。 推出mjc-fs.com...
View ArticleClik here to view.
MJC – Ancient Wisdom Meets Modern Channels
HONG KONG The ancient practice of feng shui may have been developed in China over 3,000 years ago, but it can still bring good fortune, balance and harmony to our busy lives, today. However, like...
View ArticleClik here to view.
ADCセラピューティクスが登録試験リードプログラム2件の資金2億ドルを私募調達したと発表
スイス・ローザンヌ （ビジネスワイヤ） — 主要ながんを標的にした専有的な抗体薬物複合体（ADC）の開発を専門とするオンコロジー創薬／開発企業のADCセラピューティクス（ADCT）は本日、2億ドルを私募調達したと発表しました。今回の資金調達は応募超過となり、Auven...
View ArticleClik here to view.
ABEC 4,000 Liter Single-Use Bioreactor to Expand Emergent BioSolutions...
BETHLEHEM, Pa. ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced that Emergent BioSolutions will equip their Baltimore, Maryland bulk...
View ArticleClik here to view.
ABEC 4,000升单次使用生物反应器扩大了Emergent BioSolutions的制造产能
宾夕法尼亚州伯利恒 (美国商业资讯) — 全球领先的生物制药制造一体化解决方案及服务提供商ABEC今天宣布，Emergent BioSolutions设在马里兰州巴尔的摩的大宗制造厂区（Bayview）将装备一台ABEC...
View ArticleClik here to view.
AgeX Therapeutics CEO Michael D. West to Give Special Interview for The...
ALAMEDA, Calif. AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announced today that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of...
View ArticleClik here to view.
Breakthrough Medical and Pharmaceutical Funding Awarded to Consortium That...
MELBOURNE, Australia Regenerative skin company Avita Medical is delighted to be part of Accelerating Australia, a consortium that will inject up to $2 million into a breakthrough innovation project...
View ArticleClik here to view.
Kyowa Hakko Kirin Announces Marketing Authorisation Application for...
TOKYO Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151) (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announces that its marketing authorisation application (MAA) for mogamulizumab, for the...
View Article